Current biomarkers in clinical use such as PD-L1 expression (3), mismatch repair deficiency (MMR) (4), and tumor mutational burden (TMB) (5) are being used, but they have limitations in accurately forecasting treatment response. The gene discussed is CD274; the disease is neoplasm.